Concord Biotech Limited (BOM:543960)

Market Cap	151.04B
Revenue (ttm)	11.88B
Net Income (ttm)	3.56B
Shares Out	n/a
EPS (ttm)	34.03
PE Ratio	42.42
Forward PE	34.21
Dividend	10.70 (0.74%)
Ex-Dividend Date	Sep 3, 2025

Volume	2,192
Average Volume	17,539
Open	1,455.00
Previous Close	1,452.80
Day's Range	1,436.35 - 1,458.10
52-Week Range	1,370.05 - 2,451.65
Beta	n/a
RSI	33.27
Earnings Date	Nov 7, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,571
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.